DANA LLAMAS: Open Payments
NPI 1467817783 · RIVERSIDE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,278 in 114 payments from 15 companies in 2025. Trend: 2023 $2,183 · 2024 $2,689 · 2025 $2,278
Food & beverage: $2,278
| Company | Payments | Amount |
|---|---|---|
| Incyte Corporation | 19 | $451 |
| ABBVIE INC. | 19 | $374 |
| UCB, Inc. | 18 | $355 |
| Amgen Inc. | 18 | $199 |
| GENZYME CORPORATION | 5 | $199 |
| Novartis Pharmaceuticals Corporation | 10 | $189 |
| Galderma Laboratories, L.P. | 10 | $184 |
| Janssen Biotech, Inc. | 4 | $76 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $51 |
| Arcutis Biotherapeutics, Inc. | 2 | $49 |
Products named: OPZELURA, Bimzelx, SKYRIZI, DUPIXENT, OTEZLA, COSENTYX, NEMLUVIO, RINVOQ.
Industry payments across CA — which companies pay providers there.
